PNC Financial Services Group Inc. Grows Stock Position in AbbVie Inc. $ABBV

PNC Financial Services Group Inc. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,295,432 shares of the company’s stock after acquiring an additional 209,476 shares during the period. AbbVie comprises 0.6% of PNC Financial Services Group Inc.’s portfolio, making the stock its 29th biggest position. PNC Financial Services Group Inc. owned about 0.24% of AbbVie worth $994,564,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its stake in shares of AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Hartline Investment Corp grew its stake in shares of AbbVie by 13.0% in the 2nd quarter. Hartline Investment Corp now owns 9,826 shares of the company’s stock valued at $1,824,000 after buying an additional 1,128 shares during the period. Kanawha Capital Management LLC lifted its stake in shares of AbbVie by 0.3% in the 2nd quarter. Kanawha Capital Management LLC now owns 144,470 shares of the company’s stock valued at $26,817,000 after purchasing an additional 465 shares during the last quarter. Finally, Huntleigh Advisors Inc. increased its holdings in AbbVie by 36.5% in the 2nd quarter. Huntleigh Advisors Inc. now owns 12,381 shares of the company’s stock valued at $2,298,000 after purchasing an additional 3,313 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ABBV. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Citigroup cut their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Piper Sandler restated an “overweight” rating and set a $289.00 target price (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $251.00.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Stock Up 1.8%

ABBV stock opened at $231.57 on Friday. The company has a market capitalization of $409.28 billion, a PE ratio of 98.12, a P/E/G ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The stock’s 50 day moving average is $223.56 and its two-hundred day moving average is $220.85.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the company posted $2.16 EPS. The business’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.